Drug Profile

SAR 438544

Alternative Names: SAR438544

Latest Information Update: 27 Jul 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanofi
Class Antihyperglycaemics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Type 1 diabetes mellitus

Most Recent Events

09 Jun 2017 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Type-1 diabetes mellitus presented at the 77^th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
01 Aug 2016 Discontinued - Phase-I for Type-1 diabetes mellitus in USA (SC)
24 Dec 2015 Sanofi plans a phase I trial for Type-1 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT02635243)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com